531 related articles for article (PubMed ID: 32117235)
21. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
22. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.
Lukas RV; Juhász C; Wainwright DA; James CD; Kennedy E; Stupp R; Lesniak MS
J Neurooncol; 2019 Jan; 141(1):111-120. PubMed ID: 30415456
[TBL] [Abstract][Full Text] [Related]
23. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
24. Tryptophan degradation enzymes expression in the placenta and the Kynurenine/Tryptophan ratio in maternal plasma after elective cesarean section.
Silvano A; Seravalli V; Strambi N; Vallario A; Tofani L; Parenti A; Di Tommaso M
J Reprod Immunol; 2023 Mar; 156():103823. PubMed ID: 36739732
[TBL] [Abstract][Full Text] [Related]
25. The therapeutic potential of targeting tryptophan catabolism in cancer.
Opitz CA; Somarribas Patterson LF; Mohapatra SR; Dewi DL; Sadik A; Platten M; Trump S
Br J Cancer; 2020 Jan; 122(1):30-44. PubMed ID: 31819194
[TBL] [Abstract][Full Text] [Related]
26. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
27. Tryptophan and its metabolites in normal physiology and cancer etiology.
Perez-Castro L; Garcia R; Venkateswaran N; Barnes S; Conacci-Sorrell M
FEBS J; 2023 Jan; 290(1):7-27. PubMed ID: 34687129
[TBL] [Abstract][Full Text] [Related]
28. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans.
Stapelberg M; Zobalova R; Nguyen MN; Walker T; Stantic M; Goodwin J; Pasdar EA; Thai T; Prokopova K; Yan B; Hall S; de Pennington N; Thomas SR; Grant G; Stursa J; Bajzikova M; Meedeniya AC; Truksa J; Ralph SJ; Ansorge O; Dong LF; Neuzil J
Free Radic Biol Med; 2014 Feb; 67():41-50. PubMed ID: 24145120
[TBL] [Abstract][Full Text] [Related]
29. Genetic Deficiency of Indoleamine 2,3-dioxygenase Aggravates Vascular but Not Liver Disease in a Nonalcoholic Steatohepatitis and Atherosclerosis Comorbidity Model.
Arora A; Tripodi GL; Kareinen I; Berg M; Forteza MJ; Gisterå A; Griepke S; Casagrande FB; Martins JO; Abdalla DSP; Cole J; Monaco C; Ketelhuth DFJ
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563591
[TBL] [Abstract][Full Text] [Related]
30. Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.
Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Bustamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ
Breast Cancer Res; 2020 Oct; 22(1):113. PubMed ID: 33109232
[TBL] [Abstract][Full Text] [Related]
31. Effect of water-immersion restraint stress on tryptophan catabolism through the kynurenine pathway in rat tissues.
Ohta Y; Kubo H; Yashiro K; Ohashi K; Tsuzuki Y; Wada N; Yamamoto Y; Saito K
J Physiol Sci; 2017 May; 67(3):361-372. PubMed ID: 27364617
[TBL] [Abstract][Full Text] [Related]
32. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
[TBL] [Abstract][Full Text] [Related]
33. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.
Bishnupuri KS; Alvarado DM; Khouri AN; Shabsovich M; Chen B; Dieckgraefe BK; Ciorba MA
Cancer Res; 2019 Mar; 79(6):1138-1150. PubMed ID: 30679179
[TBL] [Abstract][Full Text] [Related]
34. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
35. Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity.
Liu JJ; Raynal S; Bailbé D; Gausseres B; Carbonne C; Autier V; Movassat J; Kergoat M; Portha B
Biochim Biophys Acta; 2015 May; 1852(5):980-91. PubMed ID: 25675848
[TBL] [Abstract][Full Text] [Related]
36. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
37. Quantification of IDO1 enzyme activity in normal and malignant tissues.
Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
[TBL] [Abstract][Full Text] [Related]
38. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
39. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.
Too LK; Li KM; Suarna C; Maghzal GJ; Stocker R; McGregor IS; Hunt NH
Behav Brain Res; 2016 Oct; 312():102-17. PubMed ID: 27316339
[TBL] [Abstract][Full Text] [Related]
40. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]